Description: In the speech, the presenter will share her insights based on three aspects: 1. Investment management is an important part of the whole process of risk management; 2. Methods and processes of asset allocation as well as risk management considerations; 3. The interaction between liability and asset is critical to risk management.

Description: Learn about business Analytics in Insurance - Practical case studies and implementation.

Description: Replacement rates have historically been a tool to determine the adequacy of retirement income to maintain an individual’s standard of living. Numerous conceptual and methodological issues lie, however, beneath its simple exterior. The purpose of this paper is to examine these underlying issues for the benefit of retirement security stakeholders, pension plan sponsors, advisors, financial product providers, and individuals planning for retirement.

Description: Book review of 'Necessary Endings'.

Description: Reports the results of one application of a Future Research technique-in this case, forecasting future economic variables.

Description: An analysis of the revamped state sponsored retirement income pension gives insight into design and funding elements that might figure in reforming social security in the United States.

Description: This article is part of a 2 part series on real options analysis (ROA). Before you can understand the limitations of ROA, you must first understand the difference between risk and uncertainty. This article goes into detail explaining the vast differences between the two phenomena.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This is the second installment of a two-part series. Part I was published in the July 2023 issue of The Stepping Stone and provided guidance on how a new (re)insurance company can build an attractive work environment for actuarial talent. In part II we will focus on how to encourage those actuaries to remain with the company in the long run.

Description: Organizations representing the actuarial professions in Canada and the United States have updated the Actuaries Climate Index (ACI) with data from the winter of 2018–19, with the 1.00 value for the season contributing to an upward trend in the average ACI value for winter.